Know What's Happening in BioTech
Know What's Happening in BioTech
BioTech Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EpiciphAI, a Chinese pre‑seed biotech, is building a liquid biopsy that reads histone modifications on cell‑free chromatin to pinpoint a fragment’s tissue of origin and its disease state. Unlike most epigenetic tests that focus on DNA methylation, this platform targets chemical tags on histone proteins, potentially capturing richer information about chromatin architecture. The company’s first use case targets cancers in organs that are difficult to access with traditional biopsies. Early development aims to demonstrate diagnostic and monitoring value before scaling to broader indications.
Here is my favourite weekly 🧵- made by my dear friend @BiopharmIQ - which is a comprehensive recap of the past week in BioTech. This 🧵 gathers the best BioTech posts written by some of the best & brightest 𝕏...
A UNIST research team engineered a methanol‑tolerant *Methylobacterium extorquens* strain that grows 1.7 times faster than conventional microbes at 2.5 % methanol. Using adaptive laboratory evolution, they identified recurring mutations in the metY and kefB genes that boost detoxification and energy...
Gee, who could this "senior FDA official" be? It's a head scratcher. But he might tell Vinay Prasad that thinly veiled attacks against, oh, UniQure, and going off on advisory councils is a great way of keeping the political pot...
Scientists discovered that the ratio of polyunsaturated to monounsaturated fatty acids in the diet determines T‑cell susceptibility to ferroptosis, a form of iron‑dependent cell death. Mice fed diets with low PUFA/MUFA ratios showed higher ferroptosis resistance, leading to stronger humoral...
Canada’s Public Health Agency has signed a new agreement with CSL Seqirus to provide millions of doses of adjuvanted cell‑based influenza vaccine in the event of a WHO‑declared pandemic. The contract replaces a previous egg‑based arrangement and builds on the...
I taught medical students that insulin resistance is a mystery. It's not. A new study in Science Advances just identified the molecular trigger - mitochondrial oxidative stress. Here's what they found: > Lipid overload floods mitochondria with reactive oxygen species > This blocks GLUT4...
Alzheimer’s disease now affects 55 million people worldwide, with 10 million new cases each year, prompting researchers to explore upstream triggers beyond genetics. Texas A&M scientists have shown that chronic circadian disruption in animal models drives microglia into a stress‑primed, inflammatory state,...
The FDA staged a media call where an anonymous senior official publicly criticized UniQure’s experimental Huntington’s disease gene therapy. The official, identified only as a practicing hematology‑oncology professor, framed his comments as serving the public interest while hinting at personal...
As a medical school professor, I tell my students: disease doesn't start in your organs. It starts in your environment. A new Nature study just proved it - your zip code literally rewires your gut microbiome. Researchers studied 1,390 people and found: >...
At AAAAI 2026, Novartis presented data confirming remibrutinib’s rapid and sustained efficacy in chronic spontaneous urticaria, with a 25 mg BID dose delivering significant UAS7 reductions. Phase 2 trials also demonstrated the BTK inhibitor’s potential in peanut allergy, achieving 86.7% tolerance at...
Cognito Therapeutics secured $105 million in Series C financing to advance its Spectris device, a non‑invasive light and sound system targeting Alzheimer’s disease. Early trials showed modest cognitive benefits despite no amyloid reduction, prompting a larger pivotal study with about...
Mount Sinai, the ARC Innovation Center, and Nvidia have announced a joint effort to develop AI models capable of decoding the human genome. Leveraging Nvidia’s GPU platforms and large‑scale machine‑learning frameworks, the partnership will create tools that translate raw DNA...
Panome Bio, a multi‑omics contract research organization, unveiled an exposomics service platform that pairs untargeted Discovery Exposomics with targeted quantification of priority chemicals. The Discovery workflow leverages the MassID™ engine and a 32,000‑compound database to profile environmental exposures without prior...
Servier announced a $2.5 billion cash deal to acquire Day One Biopharmaceuticals, paying $21.50 per share—a 68% premium to the biotech’s closing price. The acquisition centers on Day One’s Ojemda, the first FDA‑approved therapy for pediatric low‑grade glioma, the most common...
Johnson & Johnson’s Tecvayli and Darzalex combination received FDA approval for second‑line multiple myeloma treatment, marking the third drug cleared under the Commissioner’s National Priority Voucher (CNPV) program. The decision was rendered in just 55 days after J&J’s filing, thanks...
Researchers discovered that polymerizing arginine amplifies its anti‑inflammatory activity, with longer polyarginine chains upregulating IL‑4 expression. An arginine trimer (3R) can self‑assemble DNA nanotubes without magnesium, serving both as a cell‑penetrating prodrug and a delivery scaffold for p65 siRNA. The...
A novel correlated plasmon‑enhanced Raman spectroscopy (CP‑ERS) platform, built on highly oriented single‑crystalline gold quantum‑dot chips, enables direct, non‑destructive probing of electronic structure and molecular vibrations in dengue virus proteins. The technique reveals previously unseen quasielastic and inelastic Raman scatterings...
A narrative review on the therapeutic potential of stem cells in neurodegenerative diseases: advances, insights, and challenges 👉"Stem cell therapy offers regenerative potential for neurodegenerative diseases. 👉Mesenchymal stem cells (MSCs), induced pluripotent stem cells, and neural stem cells show promise through neuroprotection...
Especially after the recent disappointing regulatory update regarding $QURE AMT-130 clinical candidate for treating Huntington disease and the FDA refusal to move forward 🧵👇- here is an excellent Infograph by the BBC which explains how exactly the mechanism of @uniQure_NV’s...
Immuneering Corporation announced its 2025 financial results, highlighting a 64% overall survival rate at 12 months for atebimetinib plus modified gemcitabine/nab‑paclitaxel in first‑line pancreatic cancer. The company secured FDA and EMA alignment on the design of its pivotal Phase 3 MAPKeeper 301...
Insilico Medicine and TaiGen announced that enrollment for the Phase‑I trial of ISM4808, an AI‑designed therapy for CKD‑related anemia, is now complete and the first patient has been dosed. The study comprises single‑ascending‑dose and multiple‑ascending‑dose cohorts evaluating safety and pharmacokinetics...
Researchers at the University of Melbourne have unveiled the world’s first laboratory‑based, host‑free feeding platform for the Asian longhorned tick (Haemaphysalis longicornis). The silicone‑membrane system, using defibrinated cattle blood, supports full feeding and reproduction without live animal hosts. This breakthrough...
Researchers have identified flavin‑containing monooxygenase‑2 (FMO‑2) as a shared downstream effector in several long‑lived mitochondrial mutants of Caenorhabditis elegans, including clk‑1, isp‑1 and nuo‑6. RNA interference or genetic loss of fmo‑2 shortens the extended lifespan of these mutants, confirming its...
Researchers have engineered a magnetic nanocarrier (IO@MBD) that combines γ‑Fe₂O₃ nanoparticles with a melamine‑based dendrimer to deliver doxorubicin. The platform achieves roughly 17 wt% drug loading, remains dispersible in water, and releases the drug preferentially under acidic conditions typical of tumor...
Researchers from Tezpur University and the University of Illinois Urbana‑Champaign identified blood‑based metabolic signatures that distinguish gallbladder cancer patients—both with and without gallstones—from individuals with gallstones alone. Using untargeted metabolomics, they detected 180 to 225 altered metabolites, many linked to...
Johnson & Johnson announced FDA approval of the Tecvayli (teclistamab) and Darzalex Faspro (subcutaneous daratumumab with hyaluronidase) combination for adults with relapsed/refractory multiple myeloma who have received at least one prior line of therapy. The approval is grounded in the Phase III...
Seqster has introduced 1‑Click DataLake, a real‑world data platform that aggregates anonymized electronic health‑record information from over 150 million patients and 200,000 clinicians across the United States. The solution delivers real‑time, longitudinal patient journeys to speed trial design, feasibility assessments, and...
Liberate Bio announced it has secured both exclusive and non‑exclusive licenses for patents covering chimeric antigen receptor (CAR) designs specifically engineered for myeloid cells such as monocytes and macrophages. The patents, obtained from Carisma Therapeutics and the University of Pennsylvania,...
The pharmaceutical industry has finally delivered an oral GLP‑1 weight‑loss pill, with Novo Nordisk launching an oral version of Wegovy earlier this year. Eli Lilly’s oral GLP‑1 candidate, orforglipron, is expected to receive approval imminently. Oral formulations overcome the injection barrier that...
Kainova Therapeutics, formerly Domain Therapeutics, announced a Series B funding round to advance its next‑generation GPCR‑modulating platform aimed at reversing tumor immunosuppression. The rebrand signals a strategic shift toward a broader oncology focus, leveraging GPCR pathways that control immune cell trafficking....
The European Commission unveiled a Health Package that revises the MDR/IVDR, removes the five‑year certificate cap and introduces risk‑based surveillance, while hard‑wiring cybersecurity reporting and aligning high‑risk AI obligations with the AI Act. The package also launches the first phase...
MIT Media Lab researchers have created subcellular‑sized wireless bioelectronic devices, termed “circulatronics,” that hitch a ride on monocytes to traverse the bloodstream, cross the blood‑brain barrier, and autonomously implant in inflamed brain tissue. In mouse studies the implants self‑positioned, were...
Roche and Zealand Pharma disclosed Phase‑II (ZUPREME‑1) results for petrelintide, an amylin‑analog injected weekly, in 493 overweight or obese adults (mean BMI 37 kg/m²) with weight‑related comorbidities. The trial evaluated five dose levels against placebo over 42 weeks and met its primary endpoint,...
Biopharma R&D is witnessing a rapid influx of specialized AI models for tasks such as structure prediction, retrosynthesis, and image analysis. While each tool delivers measurable benefits, their isolated deployment creates fragmented data streams, hidden costs, and increased cognitive load...
Boosted Brain Cells Erase Dementia-Linked Proteins “At nearly six months of age, when untreated mice normally have brains saturated with harmful plaques, brains of treated mice were plaque-free. Meanwhile, older mice with plaque-saturated brains at the time of treatment saw a...
New from me on $QURE and FDA. Free, no paywall. The FDA, urged to avoid controversy, creates a new headache with attack against UniQure Anonymous diatribe from a senior official plunges agency back into headlines https://t.co/ceDE0TXjdI
Researchers at POSTECH and Ewha Womans University have created “Immune‑Shield,” a sprayable adhesive microgel that locally delivers immunosuppressive drugs onto transplanted organ surfaces. The mussel‑inspired coating adheres robustly in wet environments, providing sustained release and dramatically increasing graft survival in...
HS-20093, a B7-H3-targeted antibody-drug conjugate in lung cancer: Results from the ARTEMIS-001 phase 1a/b trial https://t.co/Jr90iovVeo https://t.co/Nl2WkprjU3
The edge is always weirder and more surprising than we can imagine, excited to follow the work of these 14 scientists and innovators. My personal favorite innovator is @ceeceeboom and her 10 biobanks 👀
A recent double‑blind trial found that a combination of two GLP‑1 receptor agonists cut fat mass significantly while sparing lean muscle in adults with obesity. Over 24 weeks, participants lost an average of 5 % body fat, with lean mass decline...
$DAWN acquisition by Servier for $2.5bn is quite the ending for Ojemda. Who remembers this RAF inhibitor's bizarre & convoluted history? $BIIB $TAK https://t.co/uD5drO9ymr
Advance in neuroprotective effects of proanthocyanidins (PCs): Structure, absorption, bioactivities, mechanism, and perspectives https://t.co/AMfxcjo4m6 https://t.co/oTMCLW0CKL
Helus Pharma reported Phase II data for its psychedelic candidate HLP004, indicating symptom improvement in generalized anxiety disorder patients for up to six months. However, the trial’s low‑dose active control arm showed similar efficacy, making it difficult to isolate the...
Links between autophagy and healthy aging "Identification of autophagy modulators holds promise to improve healthspan..." https://t.co/PJjbfpeYTg https://t.co/tXreB5m4cw
Targeting immune cells in the aged brain reveals that engineered cytokine IL-10 enhances neurogenesis and improves cognition @BrunetLab https://t.co/n9bsJPSJQT https://t.co/9vvH3eEU0e
Helus Pharma reported Phase II data for its psychedelic candidate HLP004 in generalized anxiety disorder, showing symptom improvement lasting six months. However, the trial’s active low‑dose control produced outcomes similar to the therapeutic dose, making it difficult to isolate the drug’s...
Exciting news in the world of longevity via deep technology. Congratulations to @khoslaventures and @lightspeedvp on this historic investment. IMHO, Science may be bigger than OpenAI
Ergostane steroid, as one of the major contributor to cranberry derived extracellular vesicle nanoparticles, restores ovarian function of murine premature ovarian failure https://t.co/CFcjDvzMnU https://t.co/le7VTHjEKa
Exercise and enriched environments help protect brain barrier from stress-linked depression, finds study https://t.co/BcXFdEXP3f https://t.co/02j702A4Zq
